Renewal of licensing fee for the transgenic mouse strain, B-hIL2RA

The MIB is conducting pre-clinical research on photoimmunotherapy (PIT), a targeted treatment approach that uses light activation to destroy specific cells. One area of this research focuses on IL2RA, a protein expressed on regulatory T cells (Tregs). These cells can reduce the immune system’s ability to respond effectively to cancer. The objective of this work is to selectively eliminate IL2RA-expressing Tregs in order to improve anti-cancer immune responses. 

To support this research, MIB uses a transgenic mouse strain known as B-hIL2RA, which expresses the human form of IL2RA rather than the mouse form. Use of this model is essential because it enables evaluation of .... Read More